Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg After 14-day Oral Administration in Patients With Seasonal Allergic Rhinitis

NCT01400828 Phase 3 COMPLETED

The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.

Details

Lead sponsor	Yuhan Corporation
Phase	Phase 3
Status	COMPLETED
Enrolment	239
Start date	2011-06
Completion	2014-05

Conditions

• Seasonal Allergic Rhinitis

Interventions

• Bilastine
• Desloratadine
• Placebo

Primary outcomes

• AUC of TSS — 14 days
  The area under curve (AUC) of the total symptom score (TSS) since basal visit to D14 visit according to the patient's assessment

Countries

South Korea